Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Marissa DeFreitas is active.

Publication


Featured researches published by Marissa DeFreitas.


The Lancet Child & Adolescent Health | 2017

Incidence and outcomes of neonatal acute kidney injury (AWAKEN): a multicentre, multinational, observational cohort study

Jennifer G. Jetton; Louis Boohaker; Sidharth Kumar Sethi; Sanjay Wazir; Smriti Rohatgi; Danielle E. Soranno; Aftab S. Chishti; Robert Woroniecki; Cherry Mammen; Jonathan R. Swanson; Shanthy Sridhar; Craig S. Wong; Juan C Kupferman; Russell Griffin; David J. Askenazi; David T. Selewski; Subrata Sarkar; Alison L. Kent; Jeffery Fletcher; Carolyn L. Abitbol; Marissa DeFreitas; Shahnaz Duara; Jennifer R. Charlton; Ronnie Guillet; Carl D'Angio; Ayesa Mian; Erin Rademacher; Maroun J. Mhanna; Rupesh Raina; Deepak Kumar

Background Single-center studies suggest that neonatal acute kidney injury (AKI) is associated with poor outcomes. However, inferences regarding the association between AKI, mortality, and hospital length of stay are limited due to the small sample size of those studies. In order to determine whether neonatal AKI is independently associated with increased mortality and longer hospital stay, we analyzed the Assessment of Worldwide Acute Kidney Epidemiology in Neonates (AWAKEN) database. Methods All neonates admitted to 24 participating neonatal intensive care units from four countries (Australia, Canada, India, United States) between January 1 and March 31, 2014, were screened. Of 4273 neonates screened, 2022 (47·3%) met study criteria. Exclusion criteria included: no intravenous fluids ≥48 hours, admission ≥14 days of life, congenital heart disease requiring surgical repair at <7 days of life, lethal chromosomal anomaly, death within 48 hours, inability to determine AKI status or severe congenital kidney abnormalities. AKI was defined using a standardized definition —i.e., serum creatinine rise of ≥0.3 mg/dL (26.5 mcmol/L) or ≥50% from previous lowest value, and/or if urine output was <1 mL/kg/h on postnatal days 2 to 7. Findings Incidence of AKI was 605/2022 (29·9%). Rates varied by gestational age groups (i.e., ≥22 to <29 weeks =47·9%; ≥29 to <36 weeks =18·3%; and ≥36 weeks =36·7%). Even after adjusting for multiple potential confounding factors, infants with AKI had higher mortality compared to those without AKI [(59/605 (9·7%) vs. 20/1417 (1·4%); p< 0.001; adjusted OR=4·6 (95% CI=2·5–8·3); p=<0·0001], and longer hospital stay [adjusted parameter estimate 8·8 days (95% CI=6·1–11·5); p<0·0001]. Interpretation Neonatal AKI is a common and independent risk factor for mortality and longer hospital stay. These data suggest that neonates may be impacted by AKI in a manner similar to pediatric and adult patients. Funding US National Institutes of Health, University of Alabama at Birmingham, Cincinnati Children’s, University of New Mexico.


Frontiers in Pediatrics | 2016

Assessment of Worldwide Acute Kidney Injury Epidemiology in Neonates: Design of a Retrospective Cohort Study

Jennifer G. Jetton; Ronnie Guillet; David J. Askenazi; Lynn Dill; Judd Jacobs; Alison L. Kent; David T. Selewski; Carolyn L. Abitbol; Fredrick J. Kaskel; Maroun J. Mhanna; Namasivayam Ambalavanan; Jennifer R. Charlton; Ayse Akcan Arikan; Alok Bhutada; Elizabeth Bonachea; Louis Boohaker; Patrick D. Brophy; Aftab S. Chishti; Tarah T. Colaizy; F. Sessions Cole; Carl D’Angio; T. Keefe Davis; Marissa DeFreitas; Joshua Dower; Shahnaz Duara; Jeffery Fletcher; Mamta Fuloria; Jason Gien; Katja M. Gist; Stuart L. Goldstein

Introduction Acute kidney injury (AKI) affects ~30% of hospitalized neonates. Critical to advancing our understanding of neonatal AKI is collaborative research among neonatologists and nephrologists. The Neonatal Kidney Collaborative (NKC) is an international, multidisciplinary group dedicated to investigating neonatal AKI. The AWAKEN study (Assessment of Worldwide Acute Kidney injury Epidemiology in Neonates) was designed to describe the epidemiology of neonatal AKI, validate the definition of neonatal AKI, identify primary risk factors for neonatal AKI, and investigate the contribution of fluid management to AKI events and short-term outcomes. Methods and analysis The NKC was established with at least one pediatric nephrologist and neonatologist from 24 institutions in 4 countries (USA, Canada, Australia, and India). A Steering Committee and four subcommittees were created. The database subcommittee oversaw the development of the web-based database (MediData Rave™) that captured all NICU admissions from 1/1/14 to 3/31/14. Inclusion and exclusion criteria were applied to eliminate neonates with a low likelihood of AKI. Data collection included: (1) baseline demographic information; (2) daily physiologic parameters and care received during the first week of life; (3) weekly “snapshots”; (4) discharge information including growth parameters, final diagnoses, discharge medications, and need for renal replacement therapy; and (5) all serum creatinine values. Ethics and dissemination AWAKEN was proposed as human subjects research. The study design allowed for a waiver of informed consent/parental permission. NKC investigators will disseminate data through peer-reviewed publications and educational conferences. Discussion The purpose of this publication is to describe the formation of the NKC, the establishment of the AWAKEN cohort and database, future directions, and a few “lessons learned.” The AWAKEN database includes ~325 unique variables and >4 million discrete data points. AWAKEN will be the largest, most inclusive neonatal AKI study to date. In addition to validating the neonatal AKI definition and identifying risk factors for AKI, this study will uncover variations in practice patterns related to fluid provision, renal function monitoring, and involvement of pediatric nephrologists during hospitalization. The AWAKEN study will position the NKC to achieve the long-term goal of improving the lives, health, and well-being of newborns at risk for kidney disease.


The Journal of Pediatrics | 2015

Renin Angiotensin System Blocker Fetopathy: A Midwest Pediatric Nephrology Consortium Report

Shahid Nadeem; Shireen Hashmat; Marissa DeFreitas; Katherine D. Westreich; Ibrahim F. Shatat; David T. Selewski; Ali Mirza Onder; Myra Chiang; Donald J. Weaver; Julia Steinke; John Barcia; Joel Hernandez; Guillermo Hidalgo; Susan E. Ingraham; Carolyn L. Abitbol; Cynthia G. Pan; Larry A. Greenbaum

OBJECTIVES Fetuses continue to be exposed to renin angiotensin system (RAS) blockers despite their known teratogenicity and a black box warning. We hypothesized that fetopathy from in utero exposure to RAS blockers has a broader spectrum of clinical manifestations than described previously and that there are a variety of clinical scenarios leading to such exposures. STUDY DESIGN This was a retrospective study performed through the Midwest Pediatric Nephrology Consortium. Cases of RAS blocker fetopathy were identified, with determination of renal and extrarenal manifestations, timing of exposure, and the explanation for the fetal exposure. RESULTS Twenty-four cases were identified. RAS blocker exposure after the first trimester was associated with more severe renal manifestations. Chronic dialysis or kidney transplantation was required in 8 of 17 (47%) patients with RAS blocker exposure after the first trimester and 0 of 7 patients with exposure restricted to the first trimester (P = .05). Extrarenal manifestations, some not previously noted in the literature, included central nervous system anomalies (cystic encephalomalacia, cortical blindness, sensorineural hearing loss, arachnoid cysts) and pulmonary complications (pneumothorax, pneumomediastinum). RAS blocker exposure usually was secondary to absent or poor prenatal care or undiagnosed pregnancy. CONCLUSION RAS blocker fetopathy continues to be a cause of considerable morbidity, with more severe renal manifestations associated with exposure after the first trimester. A variety of significant extrarenal manifestations occur in these patients. Clinicians should emphasize the risk of fetopathy when prescribing RAS blockers to women of childbearing age.


Pediatric Nephrology | 2013

Therapeutic plasma exchange in the treatment of exertional heat stroke and multiorgan failure

Vimal Master Sankar Raj; Amanda Alladin; Brent Pfeiffer; Chryso Katsoufis; Marissa DeFreitas; Alicia Edwards-Richards; Jayanthi Chandar; Wacharee Seeherunvong; Gwenn McLaughlin; Gaston Zilleruelo; Carolyn L. Abitbol

BackgroundExertional heat stroke (EHS) results in a constellation of systemic inflammatory responses resulting in multiorgan failure and an extremely high mortality.Case Diagnosis and TreatmentsWe present the case of an 11-year-old obese male who suffered EHS with rhabdomyolysis and concurrent renal, pulmonary, and hepatic failure. Conventional therapies including continuous veno-venous hemodiafiltration (CVVHDF) were ineffective in preventing ongoing deterioration in clinical status. Liver biopsy was reported as “extensive hepatocyte ballooning” and liver-kidney transplantation was tentatively planned.ConclusionsThe addition of therapeutic plasma exchange using the Prismaflex® system (Gambro, Lakewood, CO, USA) resulted in a reversal of the inflammatory process and recovery from multiorgan failure. Liver biopsy was not a reliable indicator of irreversible hepatic injury.


Ndt Plus | 2014

Capillary rarefaction: an early marker of microvascular disease in young hemodialysis patients

Alcia Edwards-Richards; Marissa DeFreitas; Chryso Katsoufis; Wacharee Seeherunvong; Nao Sasaki; Michael Freundlich; Gaston Zilleruelo; Carolyn L. Abitbol

Background Pediatric patients with chronic kidney disease (CKD) are at increased risk of early cardiovascular disease and premature death. Abnormalities in microvascular structure and function may presage end-organ damage including vascular calcification and myocardial ischemia associated with disordered mineral metabolism. Early detection of microvascular rarefaction (reduced density of capillaries) may identify at-risk patients and prompt timely therapeutic interventions. Our objective was to study capillary rarefaction in pediatric hemodialysis (HD) patients and to determine possible associations with mineral metabolism and cardiac risk biomarkers. Methods Capillary density (CD) was measured by nailfold capillaroscopy in 19 pediatric HD patients and 20 healthy controls. Demographic and biochemical markers were collected at entry and 6-month follow-up. Results CD was significantly decreased in HD patients compared with controls with a deficit of 24 and 31% at baseline and subsequent follow-up. Maximal CD correlated significantly with intact parathyroid hormone (iPTH) (r = −0.45; P = 0.005), serum calcium (r = −0.38; P = 0.02) and 25(OH) vitamin D levels (r = +0.36; P = 0.03) in HD patients. Capillary functional measures were similar to controls. By multivariate analysis, the primary negative determinants of CD were African American race and hyperparathyroidism; whereas, glomerular disease had a positive influence on capillary rarefaction (R2 = 64.2% variance; P = 0.001). Conclusion Pediatric HD patients demonstrate a ‘structural deficit’ in CD but show preserved ‘functional integrity’. Capillary rarefaction, an early risk factor of incipient vascular calcification, was strongly associated with biomarkers of altered mineral metabolism. Further studies are warranted to determine the impact of optimizing blood pressure and metabolic control on changes in capillary rarefaction in young CKD patients.


Journal of Developmental Origins of Health and Disease | 2017

Umbilical artery histomorphometry: a link between the intrauterine environment and kidney development

Marissa DeFreitas; D. Mathur; Wacharee Seeherunvong; T. Cano; Chryso Katsoufis; Shahnaz Duara; Salih Yasin; Gaston Zilleruelo; Maria Matilde Rodriguez; Carolyn L. Abitbol

Prematurity is a risk factor for hypertension, vascular stiffness, nephron deficit and adult onset cardiorenal disease. The vascular tree and kidneys share morphogenic drivers that promote maturation in utero before 36 weeks of gestation. Vascular elastin accrual terminates after birth leaving collagen to promote vascular stiffness. Our objective was to determine if the histomorphometry of the umbilical artery, an extension of the aorta, parallels nephron mass across gestational age groups. From a cohort of 54 newborns, 32 umbilical cord specimens were adequate for evaluation. The umbilical cord was sectioned, stained with trichrome, and digitalized. Muscular and collagenous areas of the umbilical artery were measured in pixels using the Image J 1.48q software. Total kidney volume was measured by ultrasound and factored by body surface area (TKV/BSA). The umbilical artery total area was significantly greater in term v. preterm infants (9.3±1.3 v. 7.0±2.0 mm2; P<0.05) and increased with gestational age; while the percent muscular and collagen areas were independent of gestational age (R 2=0.04; P=ns). Percent muscular area correlated positively with TKV/BSA (r=0.53; P=0.002); while an increase in collagen correlated inversely with kidney mass (r=-0.53; P=0.002). In conclusion, an enhanced % muscular area and presumed vascular elasticity was associated with increased renal mass in all infants. Umbilical artery histomorphometry provides a link between the intrauterine environment, vascular and kidney development.


Journal of Pediatric Intensive Care | 2015

Therapeutic plasma exchange in familial hemophagocytic lymphohistiocytosis

Alcia Edwards-Richards; Marissa DeFreitas; Chryso Katsoufis; Asumthia Jeyapalan; Michael Nares; Carolyn L. Abitbol

Familial hemophagocytic lymphohistiocytosis is a rare, life-threatening disorder characterized by impaired cytotoxicity, hypercytokinemia and immune-mediated organ injury. We report a 7-week-old male of consanguineous parents who presented with fever, pancytopenia and multi-organ failure. Elevated inflammatory markers and hypercytokinemia led to the diagnosis of familial hemophagocytic lymphohistiocytosis, which was confirmed with genetic testing. With the fulminant multiorgan failure, therapeutic plasma exchange was instituted, using the Prismaflex® platform, followed by standard chemo-immunotherapy. There was dramatic reversal of the multi-organ failure and stabilization of the coagulopathy with this neo-adjuvant therapy. Thereafter, he was maintained in clinical remission with chemo-immunotherapy for 3 mo while awaiting stem cell transplantation.


The Journal of Pediatrics | 2014

Neonatal Kidney Size and Function in Preterm Infants: What Is a True Estimate of Glomerular Filtration Rate?

Carolyn L. Abitbol; Wacharee Seeherunvong; Marta G. Galarza; Chryso Katsoufis; Denise Francoeur; Marissa DeFreitas; Alcia Edwards-Richards; Vimal Master Sankar Raj; Jayanthi Chandar; Shahnaz Duara; Salih Yasin; Gaston Zilleruelo


Pediatric Nephrology | 2016

Assessment of kidney function in preterm infants: lifelong implications

Carolyn L. Abitbol; Marissa DeFreitas; Jose Strauss


Pediatric Nephrology | 2016

Longitudinal patterns of urine biomarkers in infants across gestational ages

Marissa DeFreitas; Wacharee Seeherunvong; Chryso Katsoufis; Satish P. RamachandraRao; Shahnaz Duara; Salih Yasin; Gaston Zilleruelo; Maria Matilde Rodriguez; Carolyn L. Abitbol

Collaboration


Dive into the Marissa DeFreitas's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Chryso Katsoufis

Boston Children's Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Shahnaz Duara

Boston Children's Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jayanthi Chandar

Boston Children's Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Salih Yasin

Boston Children's Hospital

View shared research outputs
Researchain Logo
Decentralizing Knowledge